Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAesculap AG

About this trial

The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (18 years or older)

Surgical procedure requiring urgent, primary median laparotomy, which are classified as "Class III/Contaminated" or "Class IV/Dirty-Infected" regarding the CDC classification.

Vascular surgery

Colon and rectum

Disqualifiers

Pregnancy

Breast feeding

Patients < 18 years old or patients who are still in the growth phase

Contaminated and infected areas

Trial population

High-risk patients according to the professional criteria (such as but not limited to: age, nutrition, body mass index, comorbidities, etc.) who are undergoing prophylactic mesh implantation to avoid surgical site infection after an emergency or urgent intra-abdominal laparotomy.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Prophylactic mesh

    Device

    Prevention of incisional hernia after a prophylactic mesh in high-risk patients

Treatment groups

110 Participants
are divided into 1 treatment group
Group A: Optilene® Silver Mesh Elastic1 intervention

Trial outcomes

Primary outcomes

1

Surgical Site Infection (SSI) A2/A3 rate

SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. Centers for Disease Control and Prevention Surgical Site Infection (SSI) Classification System differentiates Superficial SSI (A1), Deep Incisional SSI (A2) and Infection with involvement of organs/body cavities (A3). Only cases of A2 and A3 are considered for the Primary Outcome and are compared to rates from reference literature

Time frame
at 6 months follow-up

Secondary outcomes

1

Cumulative rate of of postoperative complications during the study period

Numbers of all postoperative complications such as mortality, burst abdomen, bowel obstruction, bulging, necrosis, fistula, wound dehiscence, hematoma, seroma, peritonitis are added to the overall complication rate that is observed over the postoperative course

Time frame
at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up
2

Cumulative Surgical Site Infection (SSI) A2/A3 rate during the study period

Number of the Surgical Site Infection (SSI) (only A2 and A3) rate at every follow-up

Time frame
at 1 month, 1 year and 2 year follow-up.
3

Incisional hernia (IH) rate during the study period

Incisional hernia (IH) is a protrusion of tissue that forms at the site of a healing surgical scar. Incisional hernia refers to abdominal wall hernia at the site of a previous surgical incision.

Time frame
repeatedly at 6 months, 1 year and 2 year follow-up.
4

Length of hospital stay

Number of days the patient has to stay in hospital after the surgery

Time frame
at discharge (approximately up to 10 days after surgery)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Aesculap AG

Lead sponsor

B.Braun Surgical SA

Collaborator

This trial is not recruiting at the moment. You can still explore other options: